Kornimate/medical-research-clean huggingface dataset:
cathepsin activatable fluorescent probe

Conditions: Sarcoma; Soft Tissue Sarcoma; Breast Cancer

Summary: real-time detection of cancer cells during surgical removal of a tumor is important. currently when tissue is removed at the time of surgery, the removed tissue goes to pathology when the margins (edges of the tissue) are examined to see if cancer cells are present. this may take a few to several days. patients tissue with positive (cancer cells present) margins may require additional therapies including surgery. the purpose of this study is to determine a safe dose of a new imaging agent (lum015), like a fluorescent contrast agent or dye, that will show in the tumor area during surgery and may help facilitate visualization of tumor for its removal.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of soft tissue sarcoma and breast cancer patients scheduled for a lumpectomy or mastectomy. * subjects must be scheduled for surgical resection of a tumor at least 1 cm in size. * performance status of 0 or 1 * able to read, understand and sign an informed consent form * must be able and willing to follow study procedures and instructions including a possible overnight stay before surgery * otherwise healthy except for the diagnosis of cancer * alt, ast, and total bilirubin within 1.5x institutional upper normal limits; and alkaline phosphatase within 2.5x institutional upper normal limits * serum creatinine of 1.5 mg or less; creatinine clearance greater than 30 ml/min * may have previously received pre-operative external beam radiation therapy for this sarcoma exclusion criteria: * pregnant or lactating * prolonged qt interval: corrected qt interval (qtc) \> 480 msec * insulin dependent diabetes * history of anaphylactic reactions to any drug or contrast agent * asthma under medical management * uncontrolled high blood pressure * severe, active co-morbidity * known substance addiction * sexually active and not willing/able to use medically acceptable forms of contraception. * obesity defined as bmi as body mass index greater than 35 kg/meter squared. * atopy or atopic syndrome * known aids * cannot have taken an investigational drug within 30 days of coming onto this study
combined neuromuscular electrical stimulation for quadriceps and triceps during pulmonary rehabilitation in copd

Conditions: Chronic Obstructive Pulmonary Disease Overlap Syndrome; Asthma

Summary: patients with copd frequently have muscle disorders. pathogenic mechanisms generate significant pathophysiological changes in the locomotor muscles structure, leading to decreased strength, decreased endurance and limited exercise capacity. pulmonary rehabilitation is the first choice therapy and training overall lower limb endurance is a priority. even if the effects of pulmonary rehabilitation are no longer to be demonstrated, it is still necessary to optimize the modalities of muscular strengthening. in fact, it is recommended to associate to this global endurance training a specific strengthening of the muscles of the lower limbs. neuromuscular electrostimulation (nmes) is a muscular strengthening technique, but this method is not used in usual practice in pulmonary rehabilitation and often only the quadriceps are concerned. in a pulmonary rehabilitation program, including sessions of nmes of the quadriceps femoris and triceps surae could increase its effectiveness. recent studies suggest that nmes can improve muscle function, exercise tolerance, dyspnea and quality of life in copd patients. a pilot study compared the effects of the combined quadriceps femoris and triceps surae versus quadriceps alone. the final evaluation showed a greater improvement in exercise capacity in favour of the combined nmes group. only two studies with small numbers of patients evaluated the effect of combined quadriceps femoris and triceps surae nmes in pulmonary rehabilitation, with encouraging results in terms of functional gain. further larger studies seem necessary to evaluate the effects of combined quadriceps femoris and triceps surae nmes in pulmonary rehabilitation. the objective of the study is to show that combined quadriceps femoris and triceps surae nmes during a pulmonary rehabilitation program provides a more significant improvement in exercise capacity compared to a standard pulmonary rehabilitation program.


Eligibility criteria:
inclusion criteria: * patient with copd stages 2 to 4 (a to d) admitted to the pulmonary rehabilitation department of the "centre hospitalier des pays de morlaix" or the "chru of brest". * patient aged 18 years or older. * patient able to consent and having signed a consent form. exclusion criteria: * patient with a history of pneumonectomy, lobectomy dated less than 6 months old * patient with an inability to complete a respiratory rehabilitation program in its entirety * patient under guardianship or curatorship * person equipped with electronic devices such as pacemakers and intracardiac defibrillators. * skin lesions and infectious foci on the area where the electrodes. * pregnant or breastfeeding women

Keywords: pulmonary rehabilitation neuromuscular electrical stimulation copd muscular strengthening
combination of cryosurgery and nk immunotherapy for recurrent sarcoma

Conditions: Recurrent Adult Soft Tissue Sarcoma

Summary: the aim of this study is the safety and efficacy of cryosurgery plus nk immunotherapy to recurrent sarcoma.

by enrolling patients with recurrent sarcoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and natural killer (nk) cells. the safety will be evaluated by statistics of adverse reactions. the efficacy will be evaluated according to local relief degree, progress free survival (pfs) and overall survival (os).

Eligibility criteria:
inclusion criteria: * all standard therapies have failed according to nccn guidelines or the patient refuses standard therapies after cancer recurrence * body tumor 1-6, the maximum tumor length \< 5 cm * kps ≥ 70, lifespan \> 6 months * platelet count ≥ 80×109/l，white blood cell count ≥ 3×109/l, neutrophil count ≥ 2×109/l, hemoglobin ≥ 80 g/l exclusion criteria: * patients with cardiac pacemaker * patients with brain metastasis * patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

Keywords: sarcoma cryosurgery nk immunotherapy
safety study of live attenuated mumps vaccines in junior high school students under 14 years old

Conditions: Mumps

Summary: this study of live attenuated mumps vaccines is an observational study in which active monitoring and passive monitoring were combined to conduct safety observation.the live attenuated mumps vaccines manufactured by sinovac (dalian) vaccine technology co., ltd.the purpose of this study is to evaluate the safety of live attenuated mumps vaccines after large-scale application and accumulate safety data for the application of live attenuated mumps vaccines,and provide scientific basis for the formulation of vaccine immunization prevention strategies.

this study of live attenuated mumps vaccines is an observational study in which active monitoring and passive monitoring were combined to conduct safety observation.the live attenuated mumps vaccines manufactured by sinovac (dalian) vaccine technology co., ltd.bao'ji, xian'yang, yan 'an and han'zhong of shaanxi province were selected as the research center.a total of 10000 junior high school students under 14 years old who voluntarily received a dose of live attenuated mumps vaccines were be enrolled.adverse reactions/events at 30 minutes, 14 days and 30 days after vaccination of live attenuated mumps vaccine were were collected by face-to-face or telephone follow-up.

Eligibility criteria:
inclusion criteria: * junior high school students under 14 years old; * the subjects and guardians of the subjects can understand and voluntarily sign the informed consent form ; * subjects and their legal guardians are able to attend follow-up visits and follow all study procedures (such as cooperating in completing safety observation notes) exclusion criteria: -
linezolid pharmacokinetics in patients with impaired renal function (ppt6)

Conditions: Renal Failure; Impaired Renal Function

Summary: renal failure patients were treated with linezolid (lzd) for proven or suspected infections by multiresistant gram-positive cocci. the aim of this study is to determine if dose adjustment of lzd is needed as a function of renal impairment or not, especially that a significant component of lzd is eliminated unchanged in urine.


Eligibility criteria:
inclusion criteria: * healthy subjects with normal renal function (clcr ˃80 ml/min); * patients with acute renal failure (rf) (30˂clcr˂80 ml/mine) * patients on long term hd with an ideal body weight of \>60 kg and a body mass index between 20 and 26 kg/m2 * passed all the screening parameters * free of any drug exposure known to interfere with the pharmacokinetics or assay of linezolid for at least 10 days prior to the study * able to communicate effectively with study personnel, be literate, and able to give consent. exclusion criteria: had a history of clinically significant organ dysfunction other than renal disease or those diseases associated with renal disease (as in case of acute rf or esrd patients) had physical examination or laboratory test results outside the inclusion such as; sitting systolic bp (sbp) of \>140 or \ 90 or \ 95 or \< 50 beats/min at screening; history of orthostatic hypotension; history of serious intolerance, allergy or sensitivity to linezolid ; history of blood dyscrasias; history of alcohol, smoking, or drug abuse; donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study; unable to tolerate vein puncture and multiple blood samplings; any surgical/medical condition that might alter the absorption, distribution, metabolism, excretion of linezolid ; or can't follow instructions, according to the investigator's opinion. -

Keywords: linezolid pharmacokinetics haemodialysis dosing adjustment eligible subjects were classified into three groups depending on their 24-h urinary creatinine clearance (clcr) values or hd status. group 1, included 6 healthy subjects with normal renal function (clcr ˃80 ml/min); group 2, included 6 patients with acute renal failure (rf) (30˂clcr˂80 ml/mine); group 3, included 6 patients on long term haemodialysis (minimum period of dialysis was 40 month while maximum period were 130 month)
anti-vegf instead of intraoperative prp in proliferative diabetic retinopathy

Conditions: Anti-VEGF; Proliferative Diabetic Retinopathy; PRP; Vitrectomy

Summary: to evaluate the efficacy and safety of vitreoretinal surgery combined with anti-vegf therapy in the replacement of intraoperative prp in pdr therapy.


Eligibility criteria:
inclusion criteria: 1. age≥18 years old; 2. type 1 or type 2 diabetes. 3. proliferative diabetic retinopathy with vitreous hemorrhage, and conservative treatment of vitreous hemorrhage without obvious absorption for 1 month requires vitreoretinal surgery; 4. the postoperative refractive medium is clear and the pupil is large enough to obtain sufficient clear fundus exclusion criteria: 1. previously received panretinal photocoagulation or unfinished panretinal photocoagulation; 2. pulling retinal detachment involving the macula or the presence of extensive fiber proliferation requires silicone oil filling; 3. anterior chamber neovascularization or neovascular glaucoma; 4. other vascular diseases such as retinal vein occlusion, arterial occlusion, etc; 5. received intraocular anti-vegf therapy or triamcinolone acetonide treatment which are still in the treatment period.
reliability of measuring walking-related performance fatigability using six minute walk test in persons with knee osteoarthritis

Conditions: Osteoarthritis; Osteoarthritis, Knee

Summary: evidence has shown that knee osteoarthritis causes an increase in base of support and a decrease in stride length and gait velocity which results in an increase in energy expenditure during walking. this increase in energy cost of walking is suggested to result in walking related performance fatigability. however, fatigue is not commonly considered in the clinical settings in term of neither assessment nor management of knee osteoarthritis. one common tool used to evaluate walking relate performance is six minute walk test and the purpose of this study is to determine the reliability of using six minute walk test to determine walking related performance fatigability in persons with knee osteoarthritis.


Eligibility criteria:
inclusion criteria: * age 40-70 years * knee oa with history not less than three months. * radiological evidences of grade iii or less on kellgren classification. * knee pain on vnrs no more than 8/10. exclusion criteria: * neuromuscular conditions that may lead to fatigue such as multiple sclerosis * signs of serious pathology (e.g., malignancy, inflammatory disorder, infection). * history of trauma or fractures in lower extremity. * signs of lumbar radiculopathy or myelopathy. * history of knee surgery or replacement. * patients on intra-articular steroid therapy within two months before the commencement of the study. * impaired skin sensation and renal function.

Keywords: osteoarthritis six minute walk test reliability fatigue fatigability
psma-pet/mri for radiation treatment planning in patients with locally metastatic prostate cancer: a pilot study

Conditions: Metastatic Prostate Cancer

Summary: this pilot study will investigate the use of psma-pet/mri (positron emission tomography/ magnetic resonance imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at the time of diagnosis. patients will undergo a single psma-pet/mri (or pet/ct (computed tomography) in some circumstances) prior to initiation of treatment. following development of a psma-pet guided radiation treatment plan, therapeutic radiation will be delivered per standard-of-care parameters and assessments of feasibility and tolerability will be performed.


Eligibility criteria:
inclusion criteria: * biopsy-proven treatment-naïve prostate adenocarcinoma with pelvic metastases known to suspected on standard-of-care staging imaging * eligibility and plan to undergo definitive radiation therapy for prostate cancer per established standard-of-care radiation oncology clinical guidelines * be at least 18 years of age exclusion criteria: * inability to tolerate or undergo pet/mri or pet/ct * previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, castleman's disease, etc.) * recurrent prostate adenocarcinoma * known distant metastatic disease * current or prior treatment for prostate cancer * known allergy to glucagon * previous diagnosis of insulinoma or pheochromocytoma
anticipated personalization of the management in day hospital unit based on a collection of the pros via a digital tool

Conditions: Solid Malignant Tumor

Summary: the present study proposes a new organization of the day hospital unit with several possible pathways defined by pro. the organization realies on a platform composed of nurses supervised by an ipa and a doctor one day before a treatment in the day hospitalization unit admission, results of pros collectyed through the cem@santé application (a french health care application) are reviewed by nurses from the platform and chemotherapy delivery is confirmed. the study is planed in 2 steps. 1. st stage: the current circuit remains unchanged (with systematic medical or nursing validation to confirm chemotherapy administration. patient satisfaction is collected at each visit to the day hospital unit for chemotherapy. 73 patients will be included in this phase. 2. nd stage: a short circuit is set up. if no contraindications are identified by the plateform with the remote pro collection, patients will undergo chemotherapy directly the next day (without any medical validation. patient satisfaction is also collected at each visit to the day hospital unit for chemotherapy. 73 patients will be included in this phase.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * patient treated for solid malignancy * patient starting a new chemotherapy or immunotherapy protocol. * patient receiving one of the following intravenous antineoplastic treatments in day hospital: nivolumab(1), pembrolizumab(1), folfox(2), folfirinox(2), xelox carboplatin, ec chemotherapy (epirubicin/cyclophosphamide) * affiliated and beneficiary to a social security system * informed and written consent note1: may be used in combination with tyrosine kinase inhibitors (tkis) note 2 :may be used in combination with bevacizumab, cetuximab or panitumumab exclusion criteria: * patient treated in neo-adjuvant situation for breast cancer * does not have a connected device (smartphone, tablet or computer) * does not have an internet connection * difficulty in filling out a questionnaire * protected adult or deprived of her liberty * pregnant or lactating woman

Keywords: pro (patient reported outcomes) chemotherapy immunotherapy satisfaction
study evaluating the efficacy of joint replacement

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: patient-related outcomes were originally designed to measure outcomes in clinical studies. they were not developed to predict outcomes, however, different studies showed close association between values achieved preoperatively and postoperative outcomes. the aim of the present trial is to identify patients with satisfactory and unsatisfactory outcomes after joint replacement and to investigate whether there are any potential predicting potential in preoperative results of the patient-related outcomes and if there exist other predicting factors for functional recovery or treatment failure after joint replacement surgery.


Eligibility criteria:
inclusion criteria: patients with primary or secondary hip- and knee osteoarthritis undergoing joint replacement surgery. exclusion criteria: 1. an inability to understand the polish language, 2. presence of neuromuscular disease and cognitive impairment, 3. having a prosthesis in another joint of the ipsilateral or contralateral lower limb placed within 6 months before the current surgery, 4. having rheumatoid arthritis, 5. symptoms in several joints (hip, knee or ankle) with expected total joint arthroplasty within 1 year.

Keywords: replacement arthroplasty patient-relevant outcome measure (prom) koos hoos
dermacyd ph_detinback tangerine mix (lactic acid) - photo evaluation

Conditions: Hygiene

Summary: the purpose of this study is to demonstrate the absence of photoirritation and photosensitization potential of the product dermacyd phdetinback tangerine mix (lactic acid).


Eligibility criteria:
inclusion criteria: * age between 18 and 60 years old; * phototype skin ii and iii; * integral skin test in the region; * willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion; exclusion criteria: * lactation or gestation * use of antiinflammatory and/or immunossupression drugs 15 days before the selection; * diseases which can cause immunity decrease, such as hiv, diabetes; * use of drug photosensitizer; * history of sensitivity or irritation for topic products; * active cutaneous disease which can change the study results; * history of photodermatosis active; * family or personal antecedent of cutaneous photoinduced neoplasias; * presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and queratoses actinium; * intense solar exposure in the study area; * use of new drugs or cosmetics during the study
cpap observance during the covid-19 (sars-cov-2) pandemic

Conditions: Sleep Apnea Syndromes

Summary: the hypothesis of this work is that the covid 19 pandemic and the associated lockdowns are likely to modify the adherence to positive airway pressure (pap) treatments among patients with sleep apnea. identifying these patients and identifying adherence "trajectories" over time would help mobilize human and telemedicine resources on the patients most in need.

the primary objective of this study is to compare pap adherence during lockdowns in 2020 with the corresponding weeks during 2019.

Eligibility criteria:
inclusion criteria: * patient treated/monitored by the adene group * treated for sleep apnea syndrome (i.e., an initial apnoea hypopnea index (iahi) ≥ 30/h or iahi ≥ 15/h (and more than 10/h respiratory-effort-related arousal or cardio-metabolic/respiratory comorbidities) associated with symptoms from among sleepiness, tiredness, snoring, headaches, hypertension, reduced vigilance, libido disorders, nocturia, choking or suffocation during sleep, daytime tiredness) * positive airway pressure (pap)-treated for at least 4 months before january 1, 2019 * continuous pap during 2019 * continuous pap during 2020 * acceptance of pap telemonitoring with consent given for data collection and data anonymization exclusion criteria: * less than 360 daily pap tele-monitored data per year for 2019 * less than 360 daily pap tele-monitored data per year for 2020

Keywords: sleep apnea positive airway pressure telemedicine covid 19
birth cohort study of china medical university

Conditions: Twin; Complicating Pregnancy; Advanced Maternal Age Pregnancy; Scarred Uterus; Overweight and Obesity

Summary: the cmubcs is a birth cohort study located in shenyang, china. its initial aim is to facilitate research on understanding the interplay between genes and environmental factors on disease etiology. data are collected regarding environmental factors, family and lifestyle, clinical experimental outcomes and imaging results of pregnant women and children from birth to 18 years old. biological samples including blood and tissue samples are also collected from the children and their parents.

early life phase (fetal and infant) is a critical period for the development of health and disease in a person's life. many adult chronic diseases, such as diabetes, cardiovascular and cerebrovascular diseases, all come from the exposure of negative environmental and behavioral factors during this period. by collecting the lifestyle data and clinical data of pregnant women at different periods, the appropriate indicators are anticipated to be selected to predict and evaluate the outcome of pregnancy and the health of the mothers and children in the long term. the status of overweight and obesity of children in shenyang and its surrounding areas are anticipated to be analyzed by descriptive and etiological analysis through collecting the lifestyle data and clinical data of different periods of pregnant women and the lifestyle data of different developmental stages of children.

Eligibility criteria:
inclusion criteria: 1. pregnant women, \<13 gestational weeks 2. permanent residents or families intended to remain in shenyang and surrounding areas 3. pregnant women who are planned to be examined and delivered in shengjing hospital. exclusion criteria: 1. pregnant women who refuse to take part in the study 2. pregnant women have diseases that might affect the results of researches, including neuropsychiatric disorders.
an open-label study , safety and tolerability of brincidofovir for post exposure prophylaxis of ebola

Conditions: Ebola Virus Disease

Summary: the purpose of this study is to determine how safe and tolerable brincidofovir (bcv) is when given for post exposure prophylaxis of ebola virus disease.

the primary objective of this study is to evaluate the safety and tolerability of bcv when administered for post-exposure prophylaxis of evd

Eligibility criteria:
inclusion criteria: * individuals have high-risk exposure to ebola virus based on cdc definitions * must be able to ingest, absorb and tolerate oral medication * as appropriate, must be willing to use adequate methods of contraception during the study and at least 6 months after their last dose of bcv exclusion criteria: -